Mesenchymal stem cell inhibition of T-helper 17 cell-

differentiation is triggered by cell–cell contact

and mediated by prostaglandin E2 via the EP4 receptor by Duffy, Michelle M. et al.
Mesenchymal stem cell inhibition of T-helper 17 cell-
differentiation is triggered by cell–cell contact
and mediated by prostaglandin E2 via the EP4 receptor
Michelle M. Duffy1, Jana Pindjakova1, Shirley A. Hanley1,
Cathal McCarthy 2, Gudrun A. Weidhofer1, Eva M. Sweeney1, Karen English3,
Georgina Shaw1, J. Mary Murphy1, Frank P. Barry1, Bernard P. Mahon3,
Orina Belton2, Rhodri Ceredig1 and Matthew D. Griffin1
1 Regenerative Medicine Institute (REMEDI), National Centre for Biomedical Engineering
Science (NCBES) and School of Medicine, Nursing and Health Sciences, National University of
Ireland, Galway, Galway, Ireland
2 School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin,
Dublin, Ireland
3 Institute of Immunology, National University of Ireland, Maynooth, Maynooth, Co. Kildare,
Ireland
Mesenchymal stem cells (MSCs) inhibit T-cell activation and proliferation but their effects on
individual T-cell-effector pathways and on memory versus naı¨ve T cells remain unclear. MSC
influence on the differentiation of naı¨ve and memory CD41 T cells toward the Th17 pheno-
type was examined. CD41 T cells exposed to Th17-skewing conditions exhibited reduced
CD25 and IL-17A expression following MSC co-culture. Inhibition of IL-17A production
persisted upon re-stimulation in the absence of MSCs. These effects were attenuated when
cell–cell contact was prevented. Th17 cultures from highly purified naı¨ve- and memory-
phenotype responders were similarly inhibited. Th17 inhibition by MSCs was reversed by
indomethacin and a selective COX-2 inhibitor. Media from MSC/Th17 co-cultures contained
increased prostaglandin E2 (PGE2) levels and potently suppressed Th17 differentiation in
fresh cultures. MSC-mediated Th17 inhibition was reversed by a selective EP4 antagonist and
was mimicked by synthetic PGE2 and a selective EP4 agonist. Activation-induced IL-17A
secretion by naturally occurring, effector-memory Th17 cells from a urinary obstruction
model was also inhibited by MSC co-culture in a COX-dependent manner. Overall, MSCs
potently inhibit Th17 differentiation from naı¨ve and memory T-cell precursors and inhibit
naturally-occurring Th17 cells derived from a site of inflammation. Suppression entails cell-
contact-dependent COX-2 induction resulting in direct Th17 inhibition by PGE2 via EP4.
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Introduction
The immune suppressive properties of mesenchymal stem
cells (MSCs) have garnered increasing attention over the past
decade and constitute a central mechanism for MSC
therapeutic benefits [1–4]. Specific modulatory effects of MSCs
from human and experimental animal sources have been
described for the differentiation, activation, proliferation and
effector functions of multiple innate and adaptive immune
cells [5–11]. Among these, MSC-mediated inhibition of
primary T-cell activation and proliferation, suppression of
DC maturation and promotion of regulatory phenotypes in
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monocyte/macrophages and T cells have been most extensively
characterised [7–9, 11, 12].
In keeping with a paracrine or ‘‘trophic’’ model of MSC func-
tion in vivo [13], various MSC-produced soluble mediators have
been implicated in these immunomodulatory effects including
IL-10, IL-6, HGF, TGF-b, chemokine ligand-2 (CCL2), HLA-G, NO,
tumor necrosis factor-inducible gene 6 protein (TSG-6), pros-
taglandin E2 (PGE2) and kyneurenine [1, 2, 7, 9, 12, 14–16]. For
some such mediators, expression by MSCs may be dependent on
pre-exposure to exogenous factors (e.g. IFN-g, TNF) or on
contact-dependent MSC/target cell cross-talk [2, 7, 16–19]. The
potential for harnessing MSC immunomodulatory properties has
been highlighted by results in pre-clinical models of auto-
immunity, allotransplantation, sepsis and acute ischemic injury
[1, 4, 7, 14, 15] as well as by outcomes from clinical trials in
inflammatory bowel disease, graft-versus-host disease and
myocardial infarction [1, 20].
T cells represent the primary effector cells for common
autoimmune diseases and for rejection of transplanted organs
and tissues [21]. Furthermore, activated memory T cells have
been implicated in non-antigen-specific forms of tissue injury
such as ischemia-reperfusion [22, 23]. In addition to the inves-
tigation of mechanisms underlying MSC inhibition of T-cell
activation, attention has also been directed toward their influence
on specific T-cell effector phenotypes including CD81 CTLs and
the Th1, Th2 and Treg sub-types of CD41 T cells which may be
more or less prominent in individual immune-mediated diseases
[12, 24–26]. In vitro and in vivo experimental evidence would
suggest that MSCs are consistently suppressive of CTL- and Th1-
mediated immune responses while being less inhibitory toward
Th2-type responses and actively promoting Treg survival and
expansion [9, 12, 27]. Less well understood for each of these
subsets are the relative effects of MSCs on naı¨ve T cells under-
going primary activation compared with previously activated, or
memory-phenotype, T cells.
The recent description of an additional CD41 T-cell subset,
termed Th17 cells, has added further complexity to our under-
standing of cellular adaptive immunity [28]. The Th17 effector
phenotype is characterised by synthesis of a signature cytokine,
IL-17A, in addition to IL-17F, IL-21, IL-22 and CCL20 [29]. Th17
cells have been shown to mediate localised tissue inflammation as
a defence against infection but also play a pathogenic role in
immunological diseases including rheumatoid arthritis, multiple
sclerosis, Crohn’s disease, psoriasis and glomerulonephritis
[28, 30, 31]. Th17 differentiation, activation and expansion are
now known to be promoted by the combined influences of several
cytokines including IL-6, TGF-b1, IL-1, IL-21 and IL-23 [29]. To
date, only a small number of studies have addressed the inter-
action between MSCs and Th17 cells with evidence emerging for
both suppressive and augmenting effects of MSCs on this Th cell
differentiation pathway [9, 14, 32–34].
In the current study, we extend the understanding of MSC-
mediated inhibition of Th17 cells and provide evidence for
potential therapeutic benefits of MSC therapies in suppressing
both de novo and ongoing pathogenic Th17 immune responses.
Results
Dose- and contact-dependent inhibition of Th17
differentiation by MSCs
C57BL/6 (B6) MSCs were co-cultured with CD41 T cells during
primary activation under Th17-skewing conditions at ratios of
1:2000–1:20. In these cultures, the day 4 concentration of
IL-17A and the surface expression level of CD25 by CD41 T cells
were reduced in a dose-dependent manner (Fig. 1A and B). When
re-stimulation of equal numbers of CD41 cells retrieved from the
cultures was carried out using anti-CD3/anti-CD28 beads, IL-17A
production was lower for cells generated in the presence of MSCs
(Fig. 1C). In multiple experiments, inhibition was consistently
observed at MSC:T-cell ratios as low as 1:400. Although IFN-g has
been reported to be necessary for triggering of maximal T-cell
inhibitory effects of MSCs under some conditions [17, 19],
omission of anti-IFN-g from the co-cultures was not associated
with more potent Th17 suppression (Supplementary Fig. S2). The
inhibitory effect of MSCs on Th17 activation was not strain-
specific being demonstrable for MSCs from BALB/c and DBA mice
(Supplemental Figs. S3A and S3B). Furthermore, B6 MSCs
inhibited IL-17A production by BALB/c CD41 T cells undergoing
primary Th17 induction (Supplemental Fig. S3C).
A requirement for initial cell–cell contact was examined using
Transwells cultures in which CD41 T cells undergoing primary
Th17 induction in the lower compartment were separated from
MSCs in the upper compartment. In these experiments, a modest
reduction in the surface level of CD25 on CD41 T cells was
observed at several MSC:T-cell ratios but reduction in IL-17A
production following re-stimulation occurred only at the highest
MSC:T-cell ratio (Fig. 2A and B). Consistently, comparable
degrees of Th17 inhibition in cultures lacking direct T-cell/MSC
contact required Zten-fold greater MSC numbers than direct
contact co-cultures.
Inhibition of Th17 induction by MSCs occurs with both
naı¨ve- and memory-phenotype T-cell responders
CD41 T cells were purified by FACS into naı¨ve- (CD25/CD62Lhi)
and memory- (CD25/CD62Llo) phenotype populations (Fig. 3A)
and were separately activated under Th17-skewing conditions.
For both responder populations, co-culture with low numbers of
MSCs (MSC:T-cell ratio 1:400) was associated with inhibition of
CD25 up-regulation (Fig. 3B) and IL-17A production upon re-
stimulation (Fig. 3C). Qualitatively similar results were observed
in a total of five similar experiments with median proportionate
inhibition of IL-17A production following re-stimulation of 26%
(range 13–66%) for memory-phenotype responders and 66%
(range 33–80%) for naı¨ve-phenotype responders. As shown in
Fig. 4, co-culture of both naı¨ve- and memory-phenotype CD41
T cells with a low ratio of MSCs was associated with a moderate
anti-proliferative effect under Th17-skewing conditions using
CFSE labelling (Fig. 4A) and a reduced proportion of IL-17A1
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cells within each generation of cell division using intracellular
staining for IL-17A (Fig. 4B and C). It was concluded that the
presence of low numbers of MSCs during a Th17-biased
activation culture of either naı¨ve or memory CD41 T cells
resulted in separate effects on T-cell proliferation and on
induction of high-level IL-17A production.
In additional experiments the specificity and direct nature of
MSC suppression of Th17 differentiation was demonstrated.
Inhibition of IL-17A secretion upon re-stimulation of Th17-
skewed naı¨ve- and memory-phenotype CD41 cells was not
apparent following co-culture with primary fibroblasts (Supple-
mental Fig. S4A). The possibility that monocyte/macrophages or
DCs were responsible for indirectly mediating MSC suppressive
effects on T-cell responders was eliminated by experiments in
which primary CD41 T-cell/MSC co-cultures were initiated with
anti-CD3/anti-CD28-coated beads rather than splenic APCs. In
this case, the Th-17-suppressive effect of MSCs for both naı¨ve and
memory CD41T cells persisted (Supplemental Fig. S4B).
The MSC suppressive effect on primary Th17 induction
is mediated by COX-2-dependent soluble factors
In order to identify potential mediators of MSC-induced Th17
suppression, experiments were carried out in which FACS-
purified naı¨ve CD41 T cells were Th17-skewed in APC-free
culture (anti-CD3/anti-CD28 beads) in the presence or absence of
MSCs (1:200 ratio) with or without blocking/inhibiting factors
for candidate mediators. The primary experimental read-out was
secretion of IL-17A following overnight stimulation of re-purified
CD41 T cells. As shown in Fig. 5A, the non-specific COX inhibitor
indomethacin reversed the MSC suppressive effect and, in some
experiments, was associated with a paradoxical increase. The
observation was consistent with induction, via T-cell–MSC
contact, of a COX-dependent soluble mediator. To test this
Figure 1. Inhibition of Th17 cell differentiation by MSCs. Purified B6
CD41 T cells were activated with anti-CD3e and splenic APCs under
Th17-skewing conditions7B6 MSCs at the indicated ratios. Results are
shown for (A) concentration of IL-17A in supernatants at day 4 as
measured by ELISA, (B) surface expression level of CD25 on CD41
T cells at day 4 (Insert: examples of anti-CD25 histograms) as measured
by flow cytometry, and (C) IL-17A concentrations in supernatants of re-
purified CD41 T cells re-stimulated for 24h with anti-CD3/anti-CD28-
coated beads. Data are mean1SD and are representative of five
individual experiments. ypo0.05 compared with no MSCs condition,
two-tailed, unpaired Student’s t-test.
Figure 2. Inhibition of Th17 cells by MSCs is limited in the absence of
cell–cell contact. CD41 T cells were activated with anti-CD3e and
splenic APCs under Th17-skewing conditions separated from B6 MSCs
at the indicated ratios in Transwells plates. (A) Surface expression of
CD25 on CD41 T cells at day 3, as measured by flow cytometry. (B) IL-
17A concentrations in supernatants of re-purified CD41 T cells
re-stimulated for 24h with anti-CD3/anti-CD28-coated beads, as
measured by ELISA. Data are mean1SD and are representative of
three individual experiments. ypo0.05 compared with the no MSCs
condition, two-tailed, unpaired Student’s t-test.
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further, culture supernatants were removed from 4-day, APC-free
Th17 cultures generated with and without indomethacin in the
presence or absence of MSCs. These supernatants were applied to
newly initiated Th17 cultures along with unconditioned medium
and MSC-conditioned medium containing equivalent concentra-
tions of Th17 inducing factors with and without indomethacin
(Fig. 5B). CD41 T cells were then re-purified from each culture
and stimulated overnight, after which IL-17A production was
measured. As shown, MSC-conditioned medium was associated
with a modest reduction in IL-17A compared with unconditioned
medium. In contrast, medium from Th17/MSC co-cultures
resulted in substantially greater reduction of IL-17A as well as
strong inhibition of CD25 up-regulation (data not shown). These
effects were entirely or predominantly absent for media derived
from indomethacin-containing cultures. Addition of medium
from Th17 cultures lacking MSCs had no suppressive effect and
was not influenced by indomethacin. Reversal of the MSC
suppressive effect on primary Th17 differentiation was also
demonstrated using NS-398, a selective COX-2 inhibitor
(Fig. 5C). Next, MSCs were FACS-purified from 4-day Th17
co-cultures and subjected to qRT-PCR and Western blotting
(Fig. 5D) using COX-1 and COX-2-specific reagents. As shown,
specific up-regulation of COX-2 in MSCs co-cultured with CD41
T cells under Th17-skewing conditions was observed at mRNA
and protein level. Blocking/inhibition experiments carried out to
examine the role of other candidate mediators (NO, IDO, IL-10,
Figure 3. MSC inhibition of Th17 differentiation of naı¨ve- and
memory-phenotype CD41 T cells. (A) Dot plots of CD41 T cells prior
to (top) and following (bottom) FACS. (B) Surface-expression of CD25
and (C) IL-17A concentration in supernatants following re-stimulation
of memory- and naı¨ve-phenotype CD41 T cells following 4 days71:400
MSCs under Th-17-skewing conditions. (B, C) Data are mean1SD and
are representative of five individual experiments. ypo0.05 compared
with no MSCs condition, two-tailed, unpaired Student’s t-test.
Figure 4. MSC inhibition of Th17 differentiation in relation to T-cell
division. FACS-purified naı¨ve- and memory-phenotype CD41 T cells
were CFSE-labelled and activated with anti-CD3e plus APCs under
Th17-skewing conditions71:200 MSCs. (A) CFSE dye dilution histo-
grams illustrating CD41 T-cell proliferation at day 4. (B) Representative
dot plots showing intracellular IL-17A staining relative to CFSE dilution
in CD41 T cells at day 4. (C) Graphic representation of the proportions
of each CD41 T-cell generation that were IL-17A1. Data are represen-
tative of three individual experiments.
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CCL2) yielded negative or minimally significant results (data not
shown). Overall, these experiments supported a conclusion that
the primary mechanism of Th17 suppression from both naı¨ve and
memory-phenotype CD41 T cells was the production of a
prostanoid mediator due to induced up-regulation of COX-2 in
MSCs following direct contact between MSCs and activated
T cells.
PGE2 is induced in Th17-MSC co-cultures and
suppresses Th17 induction through the EP4 receptor
As PGE2 has been reported to mediate multiple immune
suppressive effects of MSCs [1, 2, 7, 9, 12, 18], supernatants
from MSC/Th17 co-cultures of 6–72 h duration were analysed for
PGE2 concentration with relevant controls (Fig. 6A). Neither
MSCs cultured alone nor CD41 T cells cultured with or without
Th17-inducing reagents generated high PGE2 levels. In contrast,
MSC/T-cell co-cultures under Th17 differentiating conditions had
significant accumulation of PGE2 over 12–72 h. Interestingly,
increased PGE2 production was also observed from 12 to 24h in
MSC/T-cell co-cultures lacking Th17-inducing factors but levels
declined again between 48 and 72 h. In additional experiments,
MSCs were formally confirmed to be the predominant source of
PGE2 in MSC/Th17 co-cultures by sorting individual cell
populations following 18 h of co-culture then re-plating them
for an additional 18 h and quantifying PGE2 concentration in the
resulting supernatants (Supplementary Figs. S5, S6 and S7A).
PGE2 concentration increased in a dose-dependent manner in
Th17 cultures involving direct contact with MSCs but not in
Transwells co-cultures at the same MSC:CD41T-cell ratios
(Supplementary Fig. S8A). Additionally, PGE2 concentrations in
supernatants from fibroblast/Th17 co-culture supernatants were
not different to those of control Th17 cultures (Supplementary
Fig. S8B).
It was next determined whether MSC suppressive effects on
primary Th17 cultures were mediated by PGE2. Addition of
purified PGE2 was associated with a dose-dependent inhibition of
T-cell proliferation and IL-17A production (Fig. 6B) as well as
of CD25 surface expression and IL-17A production following
re-stimulation (data not shown). Inhibition occurred between 2
and 20nM PGE2 – within the range observed by 12 h in MSC/
Th17 co-cultures. The role of PGE2 in mediating MSC suppressive
effects on Th17 differentiation cultures was confirmed by addi-
tion of specific antagonists and agonists for candidate PGE2
receptors. IL-17A secretion by CD41 T cells re-purified from
MSC/Th17 co-cultures was restored to the same level as that of
control Th17 cultures by the highly selective EP4 receptor
antagonist L-161,982 (Fig. 6C). Similarly, EP4 antagonism
reversed the inhibition by MSCs of CD25 up-regulation on CD41
T cells (data not shown). That this observation was specifically
attributable to PGE2 produced by MSCs during co-culture was
Figure 5. Role of cyclooxygenases in MSC suppression of Th17 differentiation. (A) IL-17A production by FACS-purified, naı¨ve-phenotype CD41
T cells activated for 4 days with anti-CD3/anti-CD28 beads under Th17-skewing conditions71:200 MSCs with vehicle (DMSO) or 5 mM
indomethacin. Cells were then re-purified and stimulated overnight in equal numbers. (B) IL-17A production by CD41 T cells stimulated for 4 days
by anti-CD3/anti-CD28 beads under Th17-skewing conditions with the addition of various conditioned media then re-purified and stimulated
overnight in equal numbers. (C) IL-17A production by CD41 T cells stimulated for 4 days by anti-CD3/anti-CD28 beads under Th17-skewing
conditions71:200 MSCs in the presence of 0.1 (Low) or 1.0 mM (High) selective COX-2 inhibitor (NS-398) or equivalent volumes of vehicle then re-
purified and stimulated overnight in equal numbers. (D) Top: relative mRNA expression of COX-1 and COX-2 in MSCs purified by FACS following 4
days in culture7CD41 T cells/APC and a Th17-inducing cocktail. Results shown are mean1SD expression level relative to MSCs alone. Bottom:
Western blots for COX-1, COX-2 and b-actin of FACS-purified MSCs from the same culture conditions. (A) is representative of four individual
experiments, (B and D) are representative of two individual experiments and (C) is representative of three individual experiments. ypo0.05
compared with no MSCs condition (A and C), control medium (B), and MSC alone (D), two-tailed, unpaired Student’s t-test.
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confirmed by transfer of conditioned media from FACS-sorted
co-culture populations and relevant controls to fresh Th17
cultures in the presence or absence of EP4 antagonist (Supple-
mentary Figs. S5, S6 and S7B). In this case, only medium
conditioned by MSCs sorted from Th17/MCS co-cultures trans-
ferred a Th17 suppressive effect that was reversible by EP4
antagonism. Experiments carried out with antagonists of the EP1
and EP2 receptors (SC-51322 and AH 6809 respectively) yielded
negative results (data not shown). As further evidence of a
specific role for PGE2/EP4, the EP4 agonist L-902,688-mediated
dose-dependent inhibition of the primary induction of Th17 cells
(Fig. 6D).
MSCs suppress IL-17A secretion by effector-memory
Th17 cells from acutely obstructed kidney
Up to this point, the experiments were carried out exclusively
with primary naı¨ve and/or memory CD41 T cells undergoing
activation in vitro under short-term Th17-skewing conditions.
Making use of a unilateral ureteral obstruction (UUO)
model in which we have previously reported intra-renal
accumulation of effector-memory phenotype Th17 cells [22], it
was determined whether MSCs exert a mechanistically-similar
suppressive effect on the re-activation of committed Th17
cells from an area of ongoing tissue inflammation. As shown in
Fig. 7A, B6 mice underwent UUO for 72 h following which
CD451 cells were enriched from obstructed and contralateral
(non-obstructed) kidneys and briefly stimulated through
the T-cell receptor in the absence or presence of MSCs. In-line
with our previous findings [22], anti-CD3e-stimulation was
associated with robust secretion of IL-17A by cells from
obstructed kidneys (Fig. 7B). The presence of MSCs was
associated with dose-dependent reduction in IL-17A
concentration following either 24 or 48 h culture periods.
Qualitatively similar results were observed in a total of seven
similar experiments with median proportionate inhibition of
IL-17A production being 56% (range 19–69%) at MSC:CD451
cell ratio of 1:20. As we have previously reported [22], IL-17A
secretion was absent from stimulated cultures of CD451 cells
from non-obstructed kidneys (data not shown). The suppressive
effect of MSCs was reversed by indomethacin (Fig. 7C). Thus,
naturally occurring effector-memory Th17 cells undergoing
activation through the T-cell receptor signalling complex are
amenable to suppression by MSCs via a similar COX-2-dependent
mechanism.
Figure 6. MSC inhibition of Th17 differentiation is provided by PGE2 via EP4 receptor. (A) PGE2 concentrations in culture supernatants following 6,
12, 24, 48 and 72h of various MSC and CD41 T-cell cultures and co-cultures. MSC:T-cell ratio was 1:200. The Th17 cocktail consisted of anti-CD3/
anti-CD28-coated beads with Th17-inducing factors. (B) CFSE dilution and intracellular IL-17A analysis following re-stimulation of Th17 cultures
initiated with anti-CD3/anti-CD28-coated beads with addition of 0.2–100nM PGE2. (C) IL-17A production by CD41 T cells stimulated for 4 days by
anti-CD3/anti-CD28 beads under Th17-skewing conditions71:200 MSCs, with and without varying concentrations of selective EP4 antagonist.
Cells were then re-purified and stimulated overnight in equal numbers. (D) IL-17A production by CD41 T cells stimulated for 4 days by anti-CD3/
anti-CD28 beads under Th17-skewing conditions with varying concentrations of a selective EP4 agonist or equivalent volumes of vehicle. Cells
were then re-purified and stimulated overnight in equal numbers. (A, C and D) Data shown are mean1SD and are representative of (A) five
individual experiments, (B, D) three individual experiments and (C) four individual experiments.
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Discussion
A decade of in vitro experimentation has established that
inhibition of T-cell activation and proliferation is an important
element of MSC-mediated immune suppression [1, 2, 11].
Benefits of MSC administration in models of autoimmunity and
allotransplantation indicate corresponding in vivo effects [2, 4,
14, 32, 33]. Nonetheless, some basic issues regarding MSC/T-cell
interactions remain incompletely elucidated including the rela-
tive potency of MSC suppression of primary compared with
secondary T-cell activation, MSC influence on individual T-cell
effector programmes, the relative importance of the wide
diversity of mediators that have been linked with T-cell inhibition
and the balance between direct T-cell effects and indirect
inhibition mediated via APCs.
In the current study we have addressed such issues with a
focus on the Th17 differentiation pathway – a pro-inflammatory
Th cell effector phenotype with pathogenic potential in a range of
immune-mediated diseases [28, 29]. We demonstrate that low
numbers of MSCs are capable of suppressing de novo Th17
differentiation through a mechanism that is initiated most
potently by MSC/T-cell contact but is subsequently mediated by
PGE2 acting via the EP4 receptor. In contrast to other reported
T-cell inhibitory phenomena [17, 19], we find that IFN-g-medi-
ated triggering of MSCs was not necessary for Th17 suppression.
Furthermore, we demonstrate suppression by MSCs of
Th17 differentiation from both naı¨ve- and memory-phenotype
precursors as well as inhibition of IL-17A production by naturally
occurring effector-memory Th17 cells in a model of acute tissue
inflammation. Our initial observations of MSC effects on in vitro-
generated Th17 cells from mouse both confirm and extend results
recently reported by Ghannam et al. for human cells [9]. In
agreement with this study, we observed that mouse MSCs
inhibited the primary differentiation of Th17 cells from naı¨ve
precursors and that MSC co-culture resulted in reduced IL-17A
production by T cells during MSC-free re-stimulation [9].
Regarding the question of whether MSC suppressive effects are
exerted directly upon CD41 T cells undergoing Th17 differ-
entiation, experiments in an APC-culture system effectively rule
out an intermediary role for DCs, macrophages or other
accessory cells. As only a fraction of the CD41 T cells within
primary cultures were IL-17A1 by intracellular staining at a given
time, we cannot definitively rule out a role for an additional
T-cell population in suppressing the Th17 differentiation
programme. Nonetheless, cross-regulation by Th1 or Th2 effec-
tors during primary Th17 induction cultures is highly unlikely
given the continuous blockade of IFN-g and IL-4. Furthermore,
and in contrast to the findings of Ghannam et al. [9], we did not
detect induction of FOXP31 or IL-101 T cells in experiments
carried out using FACS-purified, naı¨ve-phenotype CD41 T cells
co-cultured with MSCs under Th17-skewing conditions (data not
shown).
From a clinical perspective, it is important to consider the
degree to which Th17 suppression by MSCs applies to pre-
activated T cells and T cells with pre-existing Th17 imprinting.
The results we present here for purified memory-phenotype
CD41 T cells and for effector-memory Th17 cells derived from
obstructed kidney indicate suppression of IL-17A secretion
comparable to that of naı¨ve CD41 T cells. In the case of memory-
phenotype CD41 T cells activated in vitro under Th17-skewing
Figure 7. MSC inhibition of in vivo-derived Th17 cells. (A) CD451 leukocytes were purified from obstructed and non-obstructed kidneys and
stimulated with low-dose anti-CD3e7MSCs followed by IL-17A measurement in culture supernatants. (B) IL-17A production by CD451 cells of
obstructed kidneys following 24 and 48 hour culture with 0, 1000, 5000, and 10 000 MSCs. (C) IL-17A production by CD451 cells of obstructed
kidneys following a 24h culture710000 MSCs with vehicle or 5 mM indomethacin. (B, C) Data shown are mean1SD and are representative of 7
individual experiments. ypo0.05 compared with (A) no MSCs or (B) vehicle at 24h. zpo0.05 compared with no MSCs at 48h (A), two-tailed, unpaired
Student’s t-test.
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conditions, MSC contact was also associated with inhibition of
proliferation and of CD25 up-regulation. These results are in-line
with the in vitro and in vivo findings of Rafei et al. for MSC
effects on MOG-specific Th17 cells in mouse EAE [14]. In addi-
tion, MSC-mediated suppression of Th17 responses has been
reported for antigen-specific Th17 cells in rat EAE and auto-
immune myasthenia gravis and in established autoimmune
diabetes mellitus in NOD mice [32, 33]. Interestingly, however,
evidence for enhancement of Th17 differentiation and IL-17A
production by MSCs and fibroblasts has also been presented in a
small number of studies [34, 35]. The reported results suggested
that MSC production of IL-6 as well as stimulation of IL-1 and/or
IL-23 secretion by APCs were responsible for the observations
[34, 35]. In our own experiments, we have observed that
administration of a non-selective COX inhibitor in MSC/Th17 co-
cultures is associated with enhancement of IL-17A secretion
compared with control Th17 cultures (Fig. 5A and our unpub-
lished observation).
We have also confirmed production of IL-6 and TGF-b1 by
MSCs co-cultured with activated T cells (our unpublished obser-
vation). Thus, it is important to consider that MSC inhibition of
Th17 cell differentiation and activation, while potent, is condi-
tional, being dependent upon opportune MSC/T-cell contact and
upon inducible mechanisms which, when absent or subject to
blockade, may unmask a paradoxical capacity for enhancement
of Th17 activity. Furthermore, in the case of naturally occurring
Th17 cells from obstructed kidney (or other sites of inflammation
and autoimmunity), additional experimental work will be
required to distinguish between direct and indirect MSC effects
on this T-cell effector phenotype.
From a mechanistic perspective, we provide compelling
evidence that the induced production of PGE2 by MSCs in direct
contact with CD41 T cells undergoing activation was primarily
responsible for suppressive effects on naı¨ve- and memory-
phenotype Th17 cells in vitro as well as on in vivo-derived
effector-memory Th17 cells. This is consistent with the report of
Ghannam et al. in which indomethacin reversed MSC-mediated
suppression of Th17 differentiation from human naı¨ve, cord-
blood CD41 T cells as well as IL-17A production by Th17 clones
[9]. By utilizing FACS to re-purify MSCs, we convincingly
demonstrate significant up-regulation of COX-2 and production
of PGE2 by these cells within 12–24h of placement in Th17-
skewing cultures. We also confirm the role of COX2 using the
selective inhibitor NS-398 and illustrate the participation of an
induced soluble mediator by medium transfer experiments.
Furthermore, we demonstrate that inhibition of Th17 cell
proliferation, CD25 up-regulation and IL-17A-secreting capacity
are reproducible by synthetic PGE2 at comparable concentrations
to those observed in Th17/MSC co-cultures. Finally, results
obtained with selective antagonists and agonists for the EP4
receptor in APC-free cultures indicate a direct action of MSC-
produced PGE2 on CD41 T cells via this receptor. These results
highlight the broad role that has been reported for PGE2 in
mediating various immune suppressive effects of MSCs [1–3, 6, 7,
9, 12, 18] while also emphasising the fact that high-level
production of this, and other, soluble mediators is dependent
upon an initial, contact-dependent cross-talk between MSCs
and target cells [2, 7, 16]. This latter consideration may be
particularly relevant to the variable efficacy of MSCs in
human clinical trials [20]. We also note that additional
mediators of MSC inhibition of Th17 cells have been reported,
primarily in the context of rodent models of tissue-
specific autoimmunity, including alternatively cleaved
CCL2, IDO and TGF-b1 [14, 32, 33]. In the co-culture systems
reported here, significant reversal of MSC-mediated Th17
suppression was not observed with blocking/inhibiting agents for
these pathways (our unpublished observations) and inhibition of
COX-2 was consistently associated with complete or almost
complete reversal of suppression. Nonetheless, given the diversity
of MSC-associated suppressive mediators that has been identified
to date [1–3], it appears likely that additional direct and indirect
mechanisms of Th17 inhibition participate under different
conditions.
Of relevance to the current study, it is clear from a number of
recent reports that the interplay between PGE2, the EP4 receptor
and immunological processes, including the Th17 differentiation
pathway, is an important but complex one. Xiao et al. demon-
strated that both PGE2 and EP4 agonists protect the heart from
ischemia reperfusion injury via EP4 [36]. Additionally, Kaba-
shima et al. [37] reported, in a mouse model of colitis that EP4-
deficient mice develop more severe disease compared with mice
deficient in other prostanoid receptors. Complementary results
were obtained in animals treated with EP4 antagonist and the
effects were associated with increased activation of T cells in the
colon of treated animals [37]. In contrast, Yao et al. [38] reported
that PGE2 enhanced expansion of Th17 cells in vitro and in vivo
through PGE2-EP4 signalling. This effect was mediated, however,
indirectly through IL-23 and, in this study, PGE2 was also shown
to dose-dependently suppress Th17 differentiation from naı¨ve
CD41 T cells in an APC-free culture system [38]. Nonetheless,
enhancement of Th17-mediated immune responses by PGE2/EP4
signalling has also been described in other experimental settings
[39, 40]. Given the pleiotropic effects and diverse cellular targets
of PGE2 in vivo, it appears unlikely that the inhibitory effects of
MSC on Th17 cell differentiation and activation can be selectively
reproduced in an active disease setting by administration
of COX-2 inhibitor or EP4 agonist. Rather, the combined effects of
PGE2 and other MSC-associated mediators may be necessary to
additionally regulate the production of Th17-promoting factors
by ancillary cell populations such as dendritic cells and mono-
cyte/macrophages [7, 12].
In conclusion, this study provides novel evidence that MSC-
derived PGE2 is highly induced in Th17-MSC co-cultures and
mediates a potent suppressive effect on primary and secondary
Th17 induction via the EP4 receptor. We propose that further
characterisation of the interactions between Th17 cells and
MSCs, including the nature of the contact-dependent signal
responsible for COX-2 up-regulation, will identify additional
opportunities for manipulation of the Th17 differentiation
program. Furthermore, suppression of IL-17A production by
Eur. J. Immunol. 2011. 41: 2840–2851 Cellular immune response 2847
& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
effector-memory Th17 cells derived from a site of ‘‘sterile
inflammation’’ indicates the potential for MSCs to ameliorate
tissue damage associated with maladaptive acute or chronic Th17
activation if delivered in the correct context.
Materials and methods
Experimental animals and reagents
Eight- to 12-wk-old female C57BL/6 (B6) and BALB/c mice were
purchased from Harlan Laboratories UK (Bicester, UK) and
housed in a specific pathogen-free facility. All animal procedures
were carried out under licence from the Irish Department of
Health and Children and approved by the NUI Galway Animal
Care Research Ethics Committee. Mouse MSC cultures were
carried out in supplemented Iscove’s modified Dulbecco’s
medium (see Supplemental Methods for details of media and
buffer compositions) (Sigma-Aldrich, St. Louis, USA). Th17 cell
culture was carried out in supplemented Dulbecco’s modified
Eagle medium. Reagents used included a range of antibody
preparations (see Supplemental Methods), recombinant mouse
TGF-b1 and IL-6 (Peprotech, Rocky Hill, NJ, USA), mouse CD3/
CD28 T-cell expander beads (Dynabeadss, Invitrogen), Indo-
methacin and PGE2 (Sigma-Aldrich), and COX-2-selective inhi-
bitor (NS-398), selective EP1 antagonist (SC-51322), selective
EP2 antagonist (AH 6809), selective EP4 antagonist (L-161,982)
and selective EP4 agonist (L-902,688) (all from Cayman
Chemicals, Ann Arbor, MI, USA).
MSC isolation and characterisation
Mouse MSCs were isolated from bone marrow according to the
method described by Peister et al. [41]. Tri-lineage differentia-
tion capacity was determined using standard chondrogenic,
adipogenic and osteogenic differentiation assays (Supplemental
Fig. S1) [18]. All experiments were carried out with passage
5–MSCs grown to 80% confluence in T175 tissue culture flasks
(Nunc-Fisher Scientific) and detached with trypsin solution
(Sigma-Aldrich). Renal cortical fibroblasts were prepared accord-
ing Alvarez et al. [42].
Cortex of kidneys from healthy adult mice was diced and
forced through a series of mesh screens (230mM, 104mM and
74mM) using a glass pestle and washes with Hank’s Balanced Salt
Solution (all from Sigma-Aldrich). The resulting cell suspensions
were re-suspended in F-12 Nutrient mixture (Gibco-Invitrogen)
mixed 1:1 with DMEM supplemented with 10% FCS, 1%
L-glutamine, 1% penicillin/streptomycin, 1% HEPES and 1% non-
essential amino acids. The cultured cells were allowed to form
colonies in 6-well tissue culture plates (Nunc-Fisher Scientific) for
7 days, then lifted using 0.2% Na2EDTA, reseeded into T75 flasks
at 1106/flask and cultured for a further 7 days before use in co-
culture experiments.
Th17 differentiation cultures
Single cell suspensions were prepared from mouse spleen and
lymph nodes by mechanical disruption and filtering through
150mM Sefar Nitex ribbon mesh (Sefar, Lancashire, UK) followed
by erythrocyte lysis in ACK lysis buffer for 3min at room
temperature. Cell suspensions were incubated with anti-mouse
CD4 microbeads (Miltenyi Biotec, Auburn, CA, USA) for 20min at
41C, washed in MACS buffer and separated using MS columns and
an OctoMACSs separator according to the manufacturer’s instruc-
tions (Miltenyi Biotec). CD41 fractions were washed in MACS
buffer, re-suspended in culture medium and used as responders in
activation cultures. CD4 fractions were depleted of remaining T
cells using anti-CD90.2 microbeads by the same protocol and were
used as APCs. For Th17 differentiation, CD41 T cells and APCs were
cultured for 4 days in 96-well round bottom plates (Sarstedt,
Nu¨mbrecht, Germany) or for 3 days in the lower compartment of
Cornings HTS Transwells 9-well permeable supports (Sigma-
Aldrich) at 1 106/mL and 2 106/mL respectively with 1mg/mL
anti-CD3e, 5mg/mL anti-IFN-g, 4mg/mL anti-IL-4, 5ng/mL TGF-b1
and 25ng/mL IL-6. In some experiments, CD41 T cells were
cultured at 1 106/mL with 1:1 Dynabeadss. Other reagents were
added as described for individual experiments.
For all co-culture experiments, MSCs or fibroblasts were re-
suspended in DMEM/10% FCS, added in graded numbers to the
wells of 96-well round bottom plates and allowed to adhere for
4 h prior to the addition of CD41 T cells/APCs or CD41 T cells/
Dynabeadss. For re-stimulation of Th17-skewed T cells from
primary cultures and co-cultures, cells were subjected to
magnetic separation using anti-CD4 microbeads with positive
column fractions saved. The resulting re-purified CD41
T cells were re-plated at 0.5106/mL in fresh medium contain-
ing 1:1 Dynabeadss with no other additions in 96-well round
bottom plates for a further 24 h. For some experiments, CD41
T cells were labelled for analysis of proliferation by flow cyto-
metry using CellTrace CFSE cell proliferation kit (Molecular
Probess, Invitrogen). Supernatants from cultures and co-cultures
were analysed by ELISA using DuoSets ELISA Development
Systems (R&D Systems, Minneapolis, MN, USA) for IL-17A and
IFN-g and a Parameter Assay Kit for PGE2 (R&D Systems).
Flow cytometry and FACS
For flow cytometry, cells were suspended in FACS buffer at
5.0106/mL, incubated with various combinations of fluoro-
chrome-labelled antibodies for 20min at 41C, then washed and
re-suspended in FACS buffer prior to being analysed using a BD
FACSCantos cytometer and FlowJos software (TreeStar, Olten,
Switzerland). For analysis of intracellular IL-17A, Brefeldin A
(GolgiPlugs 1mL/mL, BD Biosciences) was added to cultures for
8 h prior to analysis and, following surface staining, intracellular
staining was carried out using Cytofix/Cytoperms reagents. For
FACS, magnetic column-enriched CD41 T cells were incubated
for 20min in FACS sorting buffer at 41C with combinations of
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fluorochrome-labelled antibodies then sorted using a BD
FACSAriaIIssorter. In some experiments, MSCs were re-purified
from co-cultures by FACS based on CD45 surface expression and
then subjected to Western Blotting, quantitative RT-PCR
or re-cultured to generate conditioned media. Representative
examples of gating strategies used for MSC re-purification
experiments are provided in Supplementary Fig. S6. Representa-
tive gating strategies for additional flow cytometry and FACS
experiments are provided in Supplementary Fig. S9. Sorted cells
were re-analysed to ensure high purity.
Western blotting
FACS-purified MSCs were incubated for 1 h on ice in complete
lysis buffer. The protein concentration was determined using a
BCA Protein Assay Kit (Fisher Scientific) and proteins were
separated on 4–20% PreciseTM Protein Gels (Fisher Scientific) in
a Mini-Proteans Tetra Cell (Bio-Rad, Hercules, CA, USA).
Electro-transfer to Immobilion P PVDF membranes (Millipore,
Billerica, MA, USA) was performed prior to blocking for 1 h at
room temperature in 5% w/v skimmed milk powder. Membranes
were incubated with anti-mouse COX-1 (1:200), anti-mouse
COX-2 (1:200) or anti-b-actin (1:50 000) overnight at 41C
followed by washing in TBST, incubation for 1 h at room
temperature with goat anti-rabbit IgG-HRP (1:5000), develop-
ment using Immobilons Western Chemiluminescent HRP
Substrate (Millipore) and imaging on a Kodaks Image Station
4000MM Pro (Eastman Kodak, Rochester, NY, USA).
Quantitative RT-PCR
Total RNA was extracted from FACS-purified MSCs using RNeasy
Micro kits (Qiagen, Hilden, Germany). Reverse transcription was
carried out using the High Capacity cDNA Reverse Transcription
kit (Applied Biosystems). Quantitative (Real Time) RT-PCR was
performed for murine COX-1 and COX-2 (see Supplemental
Methods for primer sequences) using SYBRs Green primer pairs
and SYBRs Green PCR Master Mix with 18S rRNA as a
normalisation control. Samples were amplified on a Prism
7900HT Real-time PCR System (Applied Biosystems). Relative
quantification was performed using the comparative CT method
with results expressed as fold difference relative to the MSCs-
alone sample.
UUO in mice
UUO with preparation of cell suspensions by collagenase/DNase
digestion was conducted as previously described [22, 43]
(see also Supplemental Methods). Leukocyte-enriched fractions
were prepared from kidney cell suspensions by positive magnetic
selection using anti-CD45 microbeads (Miltenyi Biotec). CD451
cells (2106/mL) were cultured for 24–48 h in 96-well round
bottom plates with 0.01mg/mL anti-CD3e with graded numbers of
MSCs and other reagents as described for individual experiments.
Statistical analysis
Individual experiments were carried out between 2 and 7 times to
ensure reproducibility. For culture experiments, individual
conditions were generated in replicates of 3–6 and assayed
separately. Results were expressed throughout as mean1SD and
differences between conditions tested statistically by two-tailed,
unpaired Student’s t-test. Significance was assigned at po0.05.
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